Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
24.24
+0.06 (0.25%)
At close: Oct 29, 2025, 4:00 PM EDT
24.24
0.00 (0.00%)
After-hours: Oct 29, 2025, 5:20 PM EDT
Amphastar Pharmaceuticals Revenue
Amphastar Pharmaceuticals had revenue of $174.41M in the quarter ending June 30, 2025, a decrease of -4.38%. This brings the company's revenue in the last twelve months to $722.68M, up 1.37% year-over-year. In the year 2024, Amphastar Pharmaceuticals had annual revenue of $731.97M with 13.59% growth.
Revenue (ttm)
$722.68M
Revenue Growth
+1.37%
P/S Ratio
1.60
Revenue / Employee
$356,351
Employees
2,028
Market Cap
1.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 731.97M | 87.57M | 13.59% |
| Dec 31, 2023 | 644.40M | 145.41M | 29.14% |
| Dec 31, 2022 | 498.99M | 61.22M | 13.98% |
| Dec 31, 2021 | 437.77M | 87.92M | 25.13% |
| Dec 31, 2020 | 349.85M | 27.49M | 8.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AMPH News
- 2 days ago - Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025 - Accesswire
- 5 weeks ago - After Protracted Sell-Off, Amphastar Looks Like A Value Pick - Seeking Alpha
- 2 months ago - Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference - Accesswire
- 2 months ago - Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum - Benzinga
- 2 months ago - Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. - Accesswire
- 2 months ago - Amphastar Announces FDA Approval for Iron Sucrose Injection, USP - Accesswire
- 2 months ago - Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 - Accesswire